EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Updates on intratumoral therapies in melanoma

Vincent T Ma iD, Alyssa K Steimle, Janmesh D Patel, Caroline Burkey, Justin C Moser iD, Asad Javed, Hibba Tul Rehman, Mustafa Ege Seker, Alexander Birbrair, Orhan S Ozkan, Mark R Albertini, Yana G Najjar iD und 1 weitere

Cancer · 2026

DOI: 10.1002/cncr.70400 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, 2026. Verfasst von Vincent T Ma und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Melanoma, Oncolytic Virotherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health National Center for Advancing Translational Sciences, Clinical and Translational Science Award Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intratumoral therapies provide an opportunity for novel strategies in the management of advanced melanoma. These approaches deliver concentrated doses of therapeutic immune agents directly into individual tumor(s), achieving local tumor control and induction of systemic antitumor immune responses while minimizing the risk of immune‐related adverse events. Talimogene laherparepvec, a genetically modified herpes simplex virus type 1–encoding granulocyte‐macrophage colony–stimulating factor, was the first oncolytic viral therapy approved in a solid tumor indication. In pivotal trials of patients with melanoma, talimogene laherparepvec demonstrated durable responses. Building on this paradigm, next‐generation oncolytic agents incorporate additional genetic modifications, such as fusogenic proteins and immunostimulatory transgenes, to enhance local cytotoxicity and systemic immune priming. Clinical studies of intratumoral, injectable agents since 2010 have evaluated monotherapy as well as combination strategies with immune checkpoint inhibitors, revealing improved response rates and durable remissions, including in patients with immune checkpoint inhibitor‐resistant disease. This review summarizes the mechanistic rationale, preclinical evidence, and clinical development of intratumoral therapies in melanoma. Key trial outcomes, safety profiles, and practical considerations for administration are discussed. Emerging trends include image‐guided visceral injection, combinatorial regimens, and the integration of intratumoral therapy in the neoadjuvant setting. As these therapies evolve, intratumoral approaches may expand their role in melanoma management, bridging locoregional tumor control with systemic immune activation and complementing existing systemic treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaOncolytic VirotherapyHumansInjections, IntralesionalAnimalsCombined Modality TherapyImmunotherapyImmune Checkpoint InhibitorsClinical Trials as TopicBiological ProductsHerpesvirus 1, Human

Stichwörter der Autor:innen

immunotherapyintratumoral therapymelanomaoncolytic virustalimogene laherparepvectumor microenvironment

Substanzen

talimogene laherparepvecImmune Checkpoint InhibitorsBiological Products

Autor:innen und Institutionen

  • Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Department of Dermatology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • HonorHealth Research Institute, Scottsdale, Arizona, USA.
  • Arizona State University School of Medicine and Advanced Medical Engineering, Scottsdale, Arizona, USA.
  • University of Chicago Medicine, Chicago, Illinois, USA.

ORCID-Profile: Vincent T Ma, Justin C Moser, Yana G Najjar

Förderung

  • National Institutes of Health National Center for Advancing Translational Sciences
  • Clinical and Translational Science Award Program

Zitieren

APA

Ma, V. T., Steimle, A. K., Patel, J. D., Burkey, C., Moser, J. C., Javed, A., Tul Rehman, H., Seker, M. E., Birbrair, A., Ozkan, O. S., Albertini, M. R., Najjar, Y. G., & Kulkarni, R. P. (2026). Updates on intratumoral therapies in melanoma. Cancer. https://doi.org/10.1002/cncr.70400

Vancouver

Ma VT, Steimle AK, Patel JD, Burkey C, Moser JC, Javed A, et al. Updates on intratumoral therapies in melanoma. Cancer. 2026. doi:10.1002/cncr.70400

BibTeX
@article{Ma2026,
  author = {Ma, Vincent T and Steimle, Alyssa K and Patel, Janmesh D and Burkey, Caroline and Moser, Justin C and Javed, Asad and Tul Rehman, Hibba and Seker, Mustafa Ege and Birbrair, Alexander and Ozkan, Orhan S and Albertini, Mark R and Najjar, Yana G and Kulkarni, Rajan P},
  title = {Updates on intratumoral therapies in melanoma},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70400}
}
Kostenlos starten →